Learning and memory impairment induced by salvinorin a, the principal ingredient of salvia divinorum, in wistar rats

International Journal of Toxicology

Volumn 30, Issue 6, 2011, Pages 650-661

  Braida, Daniela ^a   Donzelli, Andrea ^a   Martucci, Roberta ^a   Capurro, Valeria ^a   Sala, Mariaelvina ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Drug abuse; K opioid receptor; Maze; Object recognition; Passive avoidance; Toxicity

Indexed keywords

NORBINALTORPHIMINE; SALVINORIN A; SUCROSE;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION; AVERSIVE MEMORY; CONTROLLED STUDY; EPISODIC MEMORY; LATENT INHIBITION; LEARNING DISORDER; LONG TERM MEMORY; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; NEUROTOXICITY; NONHUMAN; RAT; RECOGNITION; SALVIA; SALVIA DIVINORUM; SPATIAL MEMORY; SUGAR INTAKE;

ANIMALS; ATTENTION; AVOIDANCE LEARNING; DITERPENES, CLERODANE; HALLUCINOGENS; INHIBITION (PSYCHOLOGY); LEARNING; MALE; MAZE LEARNING; MEMORY, LONG-TERM; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA; RECOGNITION (PSYCHOLOGY); SALVIA;

RATTUS NORVEGICUS; SALVIA DIVINORUM;

EID: 84856905225     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811418538     Document Type: Article

References (79)

1. Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring non nitrogenous kappa-opioid selective agonist. Proc National Acad Sci USA. 2002;99(18):11934-11939. (Pubitemid 34994502)
2. Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl). 2004;172(2):220-224. (Pubitemid 38388772)
3. Chavkin C, Sud S, Jin W, et al. Salvinorin A, an active component of the hallucinogenic sage Salvia Divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharm Exp Ther. 2004;308(3):1197-1203. (Pubitemid 38263998)
4. Vortherms TA, Roth BL. Salvinorin A: from natural product to human therapeutics. Mol Interv. 2006;6(5):257-265. (Pubitemid 44556046)
5. Mowry M, Mosher M, Briner W. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs. 2003;35(3):379-382. (Pubitemid 37237388)
6. Brown DJ. Neuroscience. Salvia on schedule. Scientific American. 2009;301(2):20-21.
7. Sumnall HR, Measham F, Brandt SD, Cole JC. Salvia divinorum use and phenomenology: results from an online survey. J Psycho-pharmacol. 2010; doi:0269881110385596.
8. Grundmann O, Phipps SM, Zadezensky I, Butterweck V. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology. Planta Med. 2007;73(10):1039-1046. (Pubitemid 47401287)
9. Fantegrossi WE, Kugle KM, Valdes LJ, 3rd, Koreeda M, Woods JH. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol. 2005;16(8):627-633. (Pubitemid 41682197)
10. Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ. Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharm Exp Ther. 2009;328(2): 588-597.
11. Willmore-Fordham CB, Krall DM, McCurdy CR, Kinder DH. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacology. 2007;53(4):481-486. (Pubitemid 47284181)
12. Li J, Rice KC, France CP. Discriminative stimulus effects of 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. J Pharm Exp Ther. 2008;324(2):827-833. (Pubitemid 351185829)
13. Baker LE, Panos JJ, Killinger BA, et al. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology (Berl). 2009; 203(2):203-211.
14. Butelman ER, Rus S, Prisinzano TE, Kreek MJ. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in non-human primates: dissociation from classic hallucinogen effects. Psychopharmacology. 2010;210(2):253-262.
15. Carlezon WA, Béguin C, DiNieri JA, et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharm Exp Ther. 2006; 316(1):440-447. (Pubitemid 41832624)
16. John TF, French LG, Erlichman JS. The antinociceptive effect of salvinorin A in mice. Eur J Pharmacol. 2006;545(2-3):129-133.
17. McCurdy CR, Sufka KJ, Smith GH, et al. Antinociceptive profile of salvinorin A, a structurally unique kappa-opioid receptor agonist. Pharmacol Biochem Behav. 2006;83(1):109-113.
18. Zhang Y, Butelman ER, Schlussman SD, et al. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa-opioid receptors. Psychophar-macology (Berl). 2005;179(3):551-558. (Pubitemid 40674756)
19. Braida D, Limonta V, Pegorini S, et al. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology. 2007;190(4):441-448. (Pubitemid 46204461)
20. Braida D, Limonta V, Capurro V, et al. Involvement of kappa-opioid and endocannabinoid system on salvinorin A-induced reward. Biol Psychiatry. 2008;63(3):286-292.
21. Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neurophar-macology. 2004;47(suppl 1):227-241. (Pubitemid 39298267)
22. Braida D, Capurro V, Zani A, et al. Potential anxiolytic-and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol. 2009; 157(5):844-853.
23. Ebner SR, Roitman MF, Potter DN, et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accum-bens. Psychopharmacology (Berl). 2010; 210(2):241-252.
24. Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F. Studies toward the pharmacophore of salvinorin A, a potent kappa-opioid receptor agonist. J Med Chem. 2005;48(2):345-348. (Pubitemid 40139777)
25. Mello NK, Negus SS. Effects of d-amphetamine and bupre-norphine combinations on speedball (cocaineφheroin) self-administration by rhesus monkeys. Neuropsychopharmacology. 2007;32(9):1985-1994. (Pubitemid 47258514)
26. Sheffler DJ, Roth BL. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa-opioid receptor. Trends Pharmacol Sci. 2003;24(3):107-109. (Pubitemid 36293772)
27. Kivell B, Prisinzano TE. Kappa-opioids and the modulation of pain. Psychopharmacology (Berl). 2010;210(2):109-119.
28. Tejeda HA, Chefer VI, Zapata A, Shippenberg TS. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat. Psychopharmacol-ogy (Berl). 2010;210(2):231-240.
29. González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006;85(2):157-162. (Pubitemid 44468138)
30. NIDA InfoFacts. http://www.drugabuse.gov/pdf/infofacts/NationTrends.pdf. Accessed April 2011.
31. Siebert DJ. Salvia divinorum and salvinorin A: new pharmacolo-gic findings. J Ethnopharmacol. 1994;43(1):53-56. (Pubitemid 24186510)
32. Valdés LJ 3rd. Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. J Psychoactive Drugs. 1994; 26(3):277-283.
33. Wolowich WR, Perkins AM, Cienki JJ. Analysis of the psychoac-tive terpenoid salvinorin A content in five Salvia divinorum herbal products. Pharmacotherapy. 2006;26(9):1268-1272. (Pubitemid 44306887)
34. Schwarzer C. 30 years of dynorphins-new insights on their functions in neuropsychiatric diseases. Pharmacol Ther. 2009;123(3): 353-370.
35. Carey AN, Lyons AM, Shay CF, Dunton O, McLaughlin JP. Endogenous kappa-opioid activation mediates stress-induced deficits in learning and memory. J Neurosci. 2009;29(13): 4293-4300.
36. Johnson MW, Maclean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa-opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011; 115(1-2):150-155.
37. Nemeth CL, Paine TA, Rittiner JE, et al. Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl). 2010;210(2): 263-274.
38. Braida D, Pozzi M, Cavallini R, Sala M. 3,4 methylenedioxy-meth- amphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats. Behav Neurosci. 2002; 116(2):298-304. (Pubitemid 34274238)
39. Sala M, Braida D, Calcaterra P, et al. Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat. Eur J Pharmacol. 1991;194(1):45-49.
40. McCann UD, Rabin RA, Winter JC. Use of the radial maze in studies of phencyclidine and other drugs of abuse. Physiol Behav. 1987;40(6):805-809.
41. Gál G, Joel D, Gusak O, Feldon J, Weiner I. The effects of electrolytic lesion to the shell subterritory of the nucleus accumbens on delayed non-matching-to-sample and four-arm baited eight-arm radial-maze tasks. Behav Neurosci. 1997;111(1):92-103. (Pubitemid 27097520)
42. Gál K, Bárdos G. The effect of chronic alcohol treatment on the radial maze performance of rats. Neuroreport. 1994;5(4): 421-424. (Pubitemid 24128630)
43. Puma C, Deschaux O, Molimard R, Bizot JC. Nicotine improves memory in an object recognition task in rats. Eur Neuropsycho-pharmacol. 1999;9(4):323-327. (Pubitemid 29253784)
44. Pitsikas N, Rigamonti AE, Cella SG, Locatelli V, Sala M, Muller EE. Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. Eur J Pharmacol. 2001;426(3):193-200. (Pubitemid 32781777)
45. Longoni A, Braida D, Biagetti R, et al. Effects of intracerebro- ventricular administration of pirenzepine on memory processing in rats. In: Vezzadini P, Facchini A, Labò G, eds. Neuroendocrine System and Aging. Rijswijk, the Netherlands: EURAGE;1986: 293-298.
46. Ellenbroek BA, Knobbout DA, Cools AR. The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Psychopharmacology (Berl). 1997;129(2):112-120. (Pubitemid 27033666)
47. Endoh T, Matsuura H, Tanaka C, Nagase H. Nor-B: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther. 1992;316:30-42.
48. Beerepoot P, Lam V, Luu A, Tsoi B, Siebert D, Szechtman H. Effects of salvinorin A on locomotor sensitization to D2/D3 dopa-mine agonist quinpirole. Neurosci Lett. 2008;446(2-3):101-104.
49. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA Jr. Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology. 2008;33(11): 2676-2687.
50. Schmidt MD, Schmidt MS, Butelman ER, et al. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse. 2005;58(3):208-210. (Pubitemid 41443741)
51. Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa-opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001; 157(2):151-162. (Pubitemid 32802126)
52. Vohra R, Seefeld A, Cantrell FL, Clark RF. Salvia divinorum: exposures reported to a state wide poison control system over 10 years. J Emerg Med. 20011; 40(6):643-650.
53. Jamot L, Matthes HW, Simonin F, Kieffer BL, Roder JC. Differential involvement of the mu and kappa-opioid receptors in spatial learning. Genes Brain Behav. 2003;2(2):80-92. (Pubitemid 36717653)
54. Daumas S, Betourne A, Halley H, et al. Transient activation of the CA3 kappa-opioid system in the dorsal hippocampus modulates complex memory processing in mice. Neurobiol Learn Mem. 2007;88(1):94-103. (Pubitemid 46809805)
55. Sandin J, Nylander I, Georgieva J, Schött PA, Ogren SO, Terenius L. Hippocampal dynorphin B injections impair spatial learning in rats: a kappa-opioid receptor-mediated effect. Neuroscience. 1998;85(2):375-382. (Pubitemid 28218659)
56. Glass MJ, Briggs JE, Billington CJ, Kotz CM, Levine AS. Opioid receptor blockade in rat nucleus tractus solitarius alters amygdala dynorphin gene expression. Am J Physiol Regul Integr Comp Physiol. 2002;283(1):R161-R167. (Pubitemid 34863921)
57. Hiramatsu M, Watanabe E. Dynorphin A (2-13) improves mecamylamine-induced learning impairment accompanied by reversal of reductions in acetylcholine release in rats. Neuropep-tides. 2006;40(1):47-56. (Pubitemid 43255412)
58. Hiramatsu M, Kameyama T. Roles of kappa-opioid receptor agonists in learning and memory impairment in animal models. Methods Find Exp Clin Pharmacol. 1998;20(7):595-599. (Pubitemid 28484999)
59. Kuzmin A, Madjid N, Terenius L, Ogren SO, Bakalkin G. Big dynor-phin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology. 2006;31(9):1928-1937.
60. Colombo PJ, Martinez JL Jr, Bennett EL, Rosenzweig MR. Kappa-opioid receptor activity modulates memory for peck-avoidance training in the 2-day-old chick. Psychopharmacology (Berl). 1992;108(1-2):235-240.
61. Huge V, Rammes G, Beyer A, Zieglgänsberger W, Azad SC. Activation of kappa-opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse. Eur J Pain. 2009;13(2):124-129.
62. Iordanova MD, McNally GP, Westbrook RF. Opioid receptors in the nucleus accumbens regulate attentional learning in the blocking paradigm. J Neurosci. 2006;26(15):4036-4045. (Pubitemid 44315424)
63. Paine TA, Tomasiewicz HC, Zhang K, Carlezon WA Jr. Sensitivity of the five-choice serial reaction time task to the effects of various psychotropic drugs in Sprague-Dawley rats. Biol Psychiatry. 2007;62(6):687-693. (Pubitemid 47314378)
64. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science. 1986;233(4765): 774-776. (Pubitemid 16016229)
65. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004;172(4): 463-470. (Pubitemid 38650984)
66. Béguin C, Potter DN, Dinieri JA, et al. N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy. J Pharmacol Exp Ther. 2008; 324(1):188-195. (Pubitemid 350294142)
67. Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the patho-physiology of drug addiction. Pharmacol Ther. 2007;116(2): 306-321.
68. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987;40(13):1287-1292. (Pubitemid 17035103)
69. Koyama T, Fukuda K. Involvement of the kappa-opioid receptor in nitrous oxide-induced analgesia in mice. J Anesth. 2010;24(2): 297-299.
70. Steinmiller CL, Young AM. Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats. Psychopharmacology (Berl). 2008;195(4):497-507. (Pubitemid 350160484)
71. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther. 1988;246(1):255-258.
72. Wall PM, Messier C. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacology (Berl). 2002;160(3):233-244. (Pubitemid 34230675)
73. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther. 2007;323(3):838-845. (Pubitemid 350146065)
74. Jackson KJ, Carroll FI, Negus SS, Damaj MI. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinoci-ception, reward, and withdrawal in the mouse. Psychopharmacology (Berl). 2010;210(2):285-294.
75. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminer-gic pathway. Proc Natl Acad Sci USA. 1992;89(6):2046-2050.
76. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. Kappa-opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA. 2006;103(8):2938-2942.
77. Bücheler R, Gleiter CH, Schwoerer P, Gaertner I. Use of nonpro-hibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry. 2005; 38(1):1-5. (Pubitemid 40278638)
78. Paulzen M, Gründer G. Toxic psychosis after intake of the hallucinogen salvinorin A. J Clin Psychiatry. 2008;69(9):1501-1502.
79. Hunt D. Rise of hallucinogen use. US Department of Justice, Office of Justice Programs, National Institute of Justice. Publication NCJ 166607; 1997. http://www.ncjrs.org/pdffiles/166607.pdf.